Premium
A phase 1/2, open‐label, dose‐escalation study of midostaurin in children with relapsed or refractory acute leukaemia
Author(s) -
Zwaan C. Michel,
Söderhäll Stefan,
Brethon Benoit,
Luciani Matteo,
Rizzari Carmelo,
Stam Ronald W.,
Besse Emmanuelle,
Dutreix Catherine,
Fagioli Franca,
Ho Phoenix A.,
Dufour Carlo,
Pieters Rob
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15593
Subject(s) - midostaurin , medicine , oncology , refractory (planetary science) , venetoclax , leukemia , cancer research , biology , astrobiology , chronic lymphocytic leukemia
Laila Elsherif* Wimal Pathmasiri* Susan McRitchie 2 David R. Archer Kenneth I. Ataga Department of Biochemistry and Biophysics, University of North Carolina NIH Common Fund Eastern Regional Comprehensive Metabolomics Resource Core, University of North Carolina at Chapel Hill, Chapel Hill, NC, Department of Pediatrics, Emory University, Atlanta, GA, and Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, TN, USA. E-mail: kataga@uthsc.edu